| Literature DB >> 35605754 |
Se Yoon Park1, Tae Hyong Kim2, Eunjung Lee3, Mark Loeb4, Yeon Su Jeong5, Jin Hwa Kim5, Sun Mi Oh5, Sojin Cheong5, Hyein Park5, SoYea Jo5, Ji Woo Sim6.
Abstract
BACKGROUND: We aimed to analyze an outbreak caused by a vaccine breakthrough infection in a hospital with an active infection control program where 91.9% of health care workers were vaccinated.Entities:
Keywords: Breakthrough infection; COVID-19 vaccine; Health care workers; Ventilation
Mesh:
Substances:
Year: 2022 PMID: 35605754 PMCID: PMC9121639 DOI: 10.1016/j.ajic.2022.05.010
Source DB: PubMed Journal: Am J Infect Control ISSN: 0196-6553 Impact factor: 4.303
Demographics of the study participants
| Health care workers (n = 61) | Patients (n = 18) | Caregivers (n = 15) | ||
|---|---|---|---|---|
| Male | 35 (57.4) | 8 (44.4) | 4 (26.7) | .92 |
| Age, mean±SD | 42.2 ± 18.8 | 75.6 ± 18.0 | 54.9 ± 15.1 | <.001 |
| Underlying disease/condition | ||||
| Hypertension | 2 (3.3) | 12 (66.7) | 3 (20.0) | <.001 |
| Diabetes | 0 | 7 (38.9) | 0 | <.001 |
| Neurologic disease | 0 | 5 (27.8) | 0 | <.001 |
| Chronic kidney disease | 0 | 3 (16.7) | 0 | .009 |
| Cardiovascular disease | 0 | 5 (27.8) | 2 (13.3) | <.001 |
| Chronic liver disease | 0 | 2 (11.1) | 0 | .06 |
| Malignancy | 0 | 4 (22.2) | 0 | .001 |
| None | 58 (95.1) | 4 (22.2%) | 11 (73.3) | <.001 |
| Vaccination | 53 (86.9) | 8 (44.4) | 9 (60.0) | <.001 |
| ChAdOx1 (Oxford AstraZeneca) | 48 (78.7) | 1 (5.6) | 2 (13.3) | |
| BNT162b2 (BioNTech Pfizer) | 1 (1.6) | 7 (38.9) | 5 (33.3) | |
| mRNA-1273 (Moderna) | 4 (6.6) | 0 | 0 | |
| Ad.26.COV2.S (Janssen) | 0 | 0 | 1 (6.7) | |
| Combination | 0 | 0 | 1 (6.7) | |
| Partially or unvaccinated | 8 (13.1) | 10 (55.6) | 6 (40.0) | |
| Interval of vaccination and infection, median, days (IQR) | 118.0 (104.5, 121.0) | 119.5 (82.5, 139.8) | 70.0 (24.0, 94.0) | .26 |
Data are presented as number (%), unless otherwise indicated.
IQR, interquartile range; SD, standard deviation.
The first dose was ChAdOx1 and the second dose was BNT162b2.
Fig 1Epidemic curve of COVID-19 according to the main superspreading event.
Fig 2Transmission pattern according to the symptom period in the cafeteria staff.
Fig. 3(A) Distribution of COVID-19 infection on the eighth floor of the main building. (B) Distribution of COVID-19 infection on the seventh floor in the maternal and child health center.
Clinical course and outcome of the study participants
| Health care workers (n = 61) | Patients (n = 18) | Caregivers (n = 15) | ||
|---|---|---|---|---|
| Place of isolation | <.001 | |||
| Community treatment center | 52 (85.2) | 0 | 9 (60.0) | |
| Hospital | 6 (9.8) | 18 (100.0) | 6 (40.0) | |
| Home | 3 (4.9) | 0 | 0 | |
| Duration of hospitalization/isolation, days | 9 (8-10) | 13 (9-19) | 9 (6-11) | .01 |
| Clinical course | <.001 | |||
| Not hospitalized, no limitations of activities | 53 (86.9) | 0 | 9 (60.0) | |
| Not hospitalized, limitation of activities | 1 (1.6) | 0 | 0 | |
| Hospitalized, not requiring supplemental oxygen | 6 (9.8) | 7 (36.8) | 6 (40.0) | |
| Hospitalized, requiring any supplemental oxygen | 1 (1.6) | 6 (33.3) | 0 | |
| Hospitalized, requiring noninvasive ventilation or HFNC | 0 | 1 (5.6) | 0 | |
| Hospitalized, receiving invasive MV or ECMO | 0 | 0 | 0 | |
| In hospital mortality | 0 | 4 (22.2) | 0 | .001 |
Data are presented as number (%), unless otherwise indicated.
ECMO, extracorporeal membrane oxygenation; HFNC, high-flow nasal cannula; MV, mechanical ventilation.